Aptar Acquires Nanopharm and Gateway Analytical, for Approx. $50M

aptarCrystal Lake, Illinois-based AptarGroup, Inc. (NYSE: ATR) acquired Nanopharm Ltd. and Gateway Analytical LLC, two pharmaceutical services companies, for a combined enterprise value of approximately $50m.

The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.
Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization.
The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.

  • Nanopharm, located in Newport, UK, is a science-driven provider of orally inhaled and nasal drug product design and development services.
  • Gateway Analytical, located in Gibsonia, PA, provides particulate detection and predictive analytical services to customers developing injectable medicines.

The companies’ results will be included in the Pharma segment and the transactions are not expected to be dilutive to Aptar’s earnings in 2019.

Led by Gael Touya, President, and Stephan Tanda, President and CEO, Aptar is a global supplier of a broad range of innovative dispensing, sealing and active packaging solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.
The company has over 14,000 dedicated employees in 18 different countries.





Join the discussion